Siponimod Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 2 mg tablets
Reference Brands: Mayzent(US &EU)
Category:
Multiple sclerosis
Siponimod is a selective sphingosine-1-phosphate receptor modulator that blocks lymphocyte migration, reducing neuroinflammation. It decreases relapse rates, slows disability progression, and reduces lesion activity in secondary progressive multiple sclerosis. Benefits include oral administration, targeted immune modulation, improved disease stability, and enhanced quality of life for MS patients.
Product Description:
Siponimod tablets, marketed as Mayzent, are approved in the US by the FDA and in the EU via EMA for treating active secondary progressive multiple sclerosis (SPMS). Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing details, and pharmacovigilance plans. In the US, the FDA reviews detailed clinical trial and manufacturing information, while the EMA ensures compliance with regional safety and quality standards.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing